Medtronic's insulin pump recall gets FDA's highest-risk label

July 15, 2013 by Arezu Sarvestani

U.S. healthcare regulators put their highest-risk Class I label on Medtronic's Paradigm insulin infusion pump recall.

Medtronic logo

The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year.

Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp